Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

212
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
212
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

418
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
418
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

452
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
452
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
210
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

339
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
339
Seizures: Classification01:13

Seizures: Classification

406
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
406

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-Human Safety and Feasibility of Nodal and Pedal MR Lymphangiography with Gadopiclenol.

Radiology. Cardiothoracic imaging·2026
Same author

Beyond FDG PET in Epilepsy: Radiotracers Targeting Neuroreceptors and Neural Proteins.

AJNR. American journal of neuroradiology·2026
Same author

Dynamic Spinal Stenosis in Intradiscal Vacuum Phenomenon: Insights from Standing Weight Bearing CT Myelography.

AJNR. American journal of neuroradiology·2026
Same author

Ipsilateral Hip Bone Mineral Density Loss in Lipomatosis of the Sciatic Nerve with Lumbosacral Plexus Involvement: A Hypothesis-Generating Case Series.

World neurosurgery·2026
Same author

A potential Adjunctive Role of 7T MRI and Amino-Acid PET in Localizing MRI-Occult Functional Pituitary Microadenomas: A Scoping Review.

AJNR. American journal of neuroradiology·2026
Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026

Related Experiment Video

Updated: Jul 16, 2025

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

2.4K

Anti-LGI1 Autoimmune Epilepsy.

Brian J Burkett1, Derek R Johnson, Christopher H Hunt

  • 1From the Department of Radiology, Mayo Clinic, Rochester, MN.

Clinical Nuclear Medicine
|September 13, 2023
PubMed
Summary
This summary is machine-generated.

Leucine-rich glioma inactivated 1 (LGI1) autoimmune encephalitis causes treatable epilepsy and faciobrachial dystonic seizures. This case highlights characteristic 18F-FDG PET/CT imaging findings of basal ganglia hypometabolism in LGI1 encephalitis.

More Related Videos

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

2.5K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

879

Related Experiment Videos

Last Updated: Jul 16, 2025

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

2.4K
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

2.5K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

879

Area of Science:

  • Neurology
  • Immunology
  • Radiology

Background:

  • Leucine-rich glioma inactivated 1 (LGI1) autoimmune encephalitis is a treatable cause of autoimmune epilepsy.
  • It is frequently associated with faciobrachial dystonic seizures (FBDS), characterized by brief, frequent seizures affecting the arm and face.

Purpose of the Study:

  • To report a case of LGI1 autoimmune encephalitis with characteristic imaging findings.
  • To correlate imaging findings with the clinical presentation of FBDS.

Main Methods:

  • Case report of a patient with suspected LGI1 autoimmune encephalitis.
  • 18F-FDG PET/CT imaging was performed to assess brain metabolism.

Main Results:

  • The patient presented with symptoms consistent with LGI1 autoimmune encephalitis and FBDS.
  • 18F-FDG PET/CT revealed severe hypometabolism in the left basal ganglia.
  • This pattern of hypometabolism is a recognized regional abnormality in LGI1 encephalitis.

Conclusions:

  • 18F-FDG PET/CT can demonstrate characteristic regional brain hypometabolism in LGI1 autoimmune encephalitis.
  • Imaging findings, such as basal ganglia hypometabolism, support the diagnosis and understanding of this treatable epilepsy syndrome.